Skip to main content

Table 1 Demographic and clinical characteristics of the newly referred and long-term follow-up patients according to objective stratification levels

From: Risk stratification by endocrinologists of patients with type 2 diabetes in a Danish specialised outpatient clinic: a cross-sectional study

  Newly referred patients Long-term follow-up patients
  Level 1 (n = 9) Level 2 (n = 125) Level 3 (n = 111) All (n = 245) Level 1 (n = 18) Level 2 (n = 236) Level 3 (n = 165) All (n = 419)
Age (years, range) 55.3 (42–62) 62.3 (23–89) 65.8 (23–93) 63.6 (23–93) 55.3 (28–68) 63.6 (19–89) 68.6 (38–93) 65.2 (19–93)
Male sex – no. (%) 3 (33.3) 82 (65.6) 71 (64.0) 156 (63.7) 9 (50) 160 (67.8) 113 (68.5) 282 (67.3)
BMI (kg/m2)a 30.3 ± 8.2 30.5 ± 6.2 29.6 ± 5.3 30.1 ± 6.1 28.0 ± 5.3 30.1 ± 5.6 30.5 ± 5.9 30.2 ± 5.7
Diabetes duration - years 3.9 ± 5.1 5.4 ± 5.8 7.9 ± 8.0 6.5 ± 7.0 6.2 ± 5.3 8.5 ± 6.0 11.5 ± 7.1 9.6 ± 6.6
SBP (mmHg) 120.6 ± 7.0 140.6 ± 15.8 142.3 ± 24.4 140.7 ± 19.8 114.8 ± 9.1 134.0 ± 13.8 136.7 ± 17.4 134.3 ± 15.7
DBP (mmHg) 70.9 ± 5.2 81.1 ± 9.5 80.0 ± 12.7 80.3 ± 11.1 72.3 ± 5.3 78.2 ± 8.7 76.8 ± 10.1 77.4 ± 9.2
HbA1c (%) (mmol/mol) 6.3 ± 2.4 (45 ± 3) 7.1 ± 3.1 (54 ± 10) 8.5 ± 4.5 (69 ± 26) 7.7 ± 4.1 (61 ± 21) 6.1 ± 2.7 (43 ± 6) 6.8 ± 3.1 (51 ± 10) 7.6 ± 3.9 (60 ± 19) 7.1 ± 3.5 (54 ± 15)
TC (mmol/l) 4.8 ± 0.8 4.4 ± 1.0 4.3 ± 1.2 4.3 ± 1.1 4.2 ± 1.4 4.0 ± 0.8 4.1 ± 1.1 4.0 ± 0.9
LDL-C (mmol/l) 2.3 ± 0.7 2.2 ± 1.0 2.1 ± 0.9 2.2 ± 0.9 2.2 ± 1.1 1.8 ± 0.6 1.9 ± 1.0 1.8 ± 0.8
HDL-C(mmol/l) 1.7 ± 0.4 1.3 ± 0.5 1.2 ± 0.4 1.3 ± 0.5 1.4 ± 0.4 1.3 ± 0.4 1.3 ± 0.4 1.3 ± 0.4
TG (mmol/l) 1.9 ± 0.6 2.0 ± 1.2 2.3 ± 1.5 2.1 ± 1.3 1.2 ± 0.6 2.1 ± 1.2 2.2 ± 1.3 2.1 ± 1.2
Retinopathy – no. (%)         
Any stage 0 3 (2.4) 6 (5.4) 9 (3.7) 0 20 (8.5) 35 (21.2) 55 (13.1)
Macular oedema or         
proliferative retinopathy 0 0 3 (2.7) 3 (1.2) 0 0 4 (2.4) 4 (1.0)
Neuropathy – no. (%)         
Peripheral neuropathy or insufficiency 0 60 (48.0) 58 (52.3) 118 (48.2) 0 128 (54.2) 111 (67.3) 139 (33.2)
Previous or existing ulcer or Charcot foot 0 0 8 (7.2) 8 (3.3) 0 0 13 (7.9) 13 (3.1)
Nephropathy – no. (%) 0 0 36 (32.4) 36 (14.7) 0 0 89 (53.9) 89 (21.2)
Former MACE – no. (%) 0 25 (20.0) 34 (30.6) 59 (24.1) 0 45 (19.1) 51 (30.9) 96 (22.9)
>1 MACE, symptomatic CVD or NYHA II-IV – no. (%) 0 0 26 (23.4) 26 (10.6) 0 0 56 (33.9) 56 (13.4)
  1. Mean ± standard deviation
  2. BMI body mass index; SBP systolic blood pressure; DBP diastolic blood pressure; HbA1c haemoglobin A1c; TC total cholesterol; LDL low density lipoprotein; HDL high density lipoprotein; TG triglycerides; CVD cardiovascular disease; MACE major cardiovascular event; NYHA the New York Heart Association functional classification in patients with heart disease [36]